The limitation of lipotransfection with plasmid vectors is its low efficiency and the short-term expression of introduced genes. This is particularly important when the synthesis of high amounts of therapeutic products is required. However, growth factors with paracrine action overcome this problem. The aim of our study was to check whether the amounts of vascular endothelial growth factor (VEGF) generated after plasmid lipotransfection into vascular smooth muscle cells (VSMC) can be sufficient to stimulate endothelial cell proliferation.
Introduction
Vascular endothelial growth factor (VEGF) induces proliferation of endothelial cells and increases permeability of the vessel wall. 1, 2 A group of related growth factors includes VEGF-A, VEGF-B, VEGF-C, VEGF-D and placenta-derived growth factor (PlGF). 1, 2 The physiological activity of VEGF-A is exerted via the specific tyrosine kinase receptors, VEGFR-1 (flt-1) VEGFR-2 (flk-1/KDR), VEGFR-3 and neuropilin, present particularly on endothelial cells. [2] [3] [4] VEGF-A is produced by different cell types, including vascular smooth muscle cells (VSMC), macrophages, fibroblasts, and tumor and endothelial cells. 2, [5] [6] [7] [8] [9] [10] [11] The expression of several known VEGF-A isoforms is induced by hypoxia, growth factors such as TGF␤, bFGF or PDGF, and by cytokines such as IL-1␤ and IL-6. [7] [8] [9] [10] [11] VEGF-A is generated in several isoforms, resulting from alternative splicing of VEGF pre-mRNA. 2 The most common isoforms are VEGF 121 and VEGF 165 , which consist of 121 and 165 amino acids, respectively. 2 The longer VEGF 189 and VEGF 206 isoforms are also synthesized. 2 Owing to the presence of an N-terminal signal sequence, VEGF is secreted from the cells. The shortest isoform, VEGF 121 , does not bind to extracellular matrix, while VEGF 165 is partially free and partially bound, and VEGF 189 and VEGF 206 are largely bound to heparan sulfate. 2 Despite VEGF generation by ischemic tissues, angiogenesis observed in chronic heart or leg ischemia is often inadequate. It is possible that the amount of synthesized VEGF is not sufficient. Indeed, supplementation with exogenous VEGF protein 12 or delivery of expression plasmids with VEGF cDNA 13 improves vascularization of ischemic tissue. An insufficient amount and/or activity of VEGF may also contribute to inadequate regeneration of endothelium after balloon angioplasty of atherosclerotic arteries. 14, 15 Additionally, the early intrauterine death of mouse embryos possessing only one allele of the VEGF gene 16, 17 supports the hypothesis that a critical amount of VEGF is required for vasculogenesis.
Administration of exogenous VEGF gene or protein stimulates collateral circulation and re-endothelialization. 12, 14 Systemic administration of VEGF protein may, however, result in significant side-effects, such as systemic hypotension, edema owing to vascular permeability or promotion of tumor growth, and metastases. 2, 18 Effective use of the protein may additionally require multiple administrations. Therefore, gene therapy may be a superior therapeutic alternative as a form of angiogenic therapy, potentially requiring only a single local administration.
Different vehicles can be used for delivery of therapeutic DNA. Retroviral vectors have the advantage of efficient cell entry and stable integration of the transgene into the host genome. However, the retroviruses can infect only dividing cells, so non-proliferating vascular cells are not an optimal target. Myoblast gene transfer may circumvent this problem, 19 but will likely require the development of regulable vectors. [20] [21] [22] Additionally, the retroviral vectors may cause insertional mutagenesis in the infected cell. 23 Another approach is to use adenoviral vectors, which can efficiently infect the non-dividing cells. They do not integrate into cell genome and thus they cannot induce neoplastic transformation. 21, 24 However, both wild-type viruses and first generation of adenoviral vectors (with deletion of E1 early genes) elicit strong immunological response, destruction of the transfected cells and reduced transgene expression. 25, 26 The simplest method for gene delivery is the use of naked DNA, although transfection efficiency is extremely low (for an intramuscular injection only about 0.5% of exposed cells are transfected). The transfection efficiency may be improved by using cationic liposomes to deliver these vectors. In studies performed in vivo in mice, 27, 28 pigs 29 and humans, 30, 31 no adverse effects or symptoms of inflammatory responses ascribable to the treatment with cationic liposomes were reported.
Nevertheless, the transfection efficiency of lipotransfection with plasmid vectors is also low and expression of the introduced genes is transient. 32 However, these may not be serious deficiencies for gene therapy of restenosis or angiogenesis, which may require only temporary expression of therapeutic genes for stimulation of re-endothelialization or neovascularization. Moreover, the low transfection efficiency may be overcome if the therapeutic product has paracrine effects and is secreted in efficacious amounts by the transfected cells.
Vascular smooth muscle cells (VSMC) are more resistant to transfection in comparison with other cell types. 33 Transfection efficiency is very low, ranging from 0.1% to 1% for rabbit, rat or human VSMC. 33 However in our hands, lipotransfection with Maxifectin or Tfx-50 attains about 5% efficiency. 34 The aim of this study was to determine whether the amounts of VEGF protein generated after plasmid lipotransfection of VSMC were sufficient to have a biological effect. Indeed, we find that, despite low transfection efficiency, transgene expression using the lipotransfection technique results in sufficient VEGF production to induce proliferation of endothelial cells exposed to the conditioned medium from transfected VSMC cells. [33] [34] [35] [36] [37] [38] [39] [40] (Poznań, Poland) or ARK (Darmstadt, Germany). Reagents for non-radioactive hybridization were obtained from Boehringer Mannheim (Mannheim, Germany), VEGF ELISA Kit, anti-VEGF antibodies for immunohistochemical staining, and anti-VEGF neutralizing antibodies from R&D (Abingdon, UK). Other anti-VEGF antibodies for immunohistochemical staining were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). All other chemicals, including recombinant human VEGF, were obtained from Sigma (St Louis, MO, USA).
Materials and methods

Reagents
Cells COS-7 cells (a transformed cell line derived from monkey kidney fibroblasts) were purchased from ATCC (Manassos, VA, USA) and human coronary artery endothelial cells (CAEC) were from Clonetics (CellSystems, St Katharine, Germany). Human umbilical vein endothelial cells (HUVEC) were isolated from placenta obtained from natural delivery, according to standard protocol. 35 
Plasmids
Cloned into the BamHI site of pSG5 mammalian expression plasmid (containing an SV40 promotor and a ␤-globin intron) were hVEGF 121 and hVEGF 165 cDNA (kindly obtained from Dr Judith Abraham (Scios Nova, Sunnyvale, CA, USA). 36 The new plasmids, pSG5-VEGF 121 and pSG5-VEGF 165 were introduced and amplified in HB101 bacteria growing on agar with ampicilin (100 g/ml).
Transfection of COS-7 and VSMC
COS7 cells
The cells were grown in DMEM medium with 10% FCS. Transfection was performed in six-well plates (Nunc, USA), at 60-80% of culture confluency. For each well, Lipofectamine (2 g/l) was added to 100 l of Optimem medium and left for 40 min. Then, the Lipofectamine solution was mixed with 2 g of plasmid DNA diluted in 100 l of Optimem and left for 15 min. After addition of 800 l of Optimem, the mixture was poured onto the cells and left for 5 h at 37°C. Then, 1 ml of DMEM medium with 20% FCS was added to each well and left for additional 19 h. Some 24 h later the transfection mixture was removed and the cells were cultured in DMEM/10% FCS for 48 or 72 h.
VSMC
Rat VSMC were obtained from thoracic aorta using collagenase treatment and cultured in DMEM F-12 medium with 5% FCS. Transfection using Lipofectin and Transfectam liposomes was performed according to vendor protocols, but was ineffective for VSMC. 34 Our earlier studies 34 revealed that the best transfection efficiency in VSMC was obtained with Maxifectin reagents, which were used in following experiments. In this case, 1 g of plasmid DNA was dissolved in 100 l of binding buffer (10 mM HEPES, 0.9% NaCl, pH 7.4) containing 2 l of enhancer solution. Then, 100 l of binding buffer containing 10 l of liposomes was added and mixture was left for 15 min. This mixture was added to the 1.8 ml of DMEM F-12 with 5% FCS that was bathing the VSMC. The medium was changed after 24 h.
In the final experiments, the Tfx-50 liposome was used for transfection of VSMC, according to the manufacturer's protocol.
Estimation of transfection efficiency
Gene transfer efficiency was estimated using transfection with pSV␤-galactosidase plasmid. After 48-96 h, the cells were washed with PBS without Ca 2+ and Mg 2+ , fixed for 15 min in 0.3% glutaraldehyde, again extensively washed with PBS, and then incubated with X-gal solution (0.2% X-gal, 2 mM MgCl 2 , 5 mM K 4 Fe(CN) 6 , 5 mM K 3 Fe(CN) 6 ) overnight. Transfection efficiency was estimated by counting the blue-stained cells in 100 random fields of the culture well and expressing these as a percentage of the total cell number.
Expression of pSG5-VEGF plasmids
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated from the transfected VSMC cells with a Total RNA Extraction Kit. We performed RT-PCR on 600 ng of total RNA using primers specific for human VEGF cDNA. The primers were designed to amplify both VEGF 165 and VEGF 121 mRNA. The sequence of the antisense primer (performs RT) was 5′-CAC CGC CTC GGC TTG TCA CAT and the sense primer was 5′-CTG CTG TCT TGG GTG CAT TGG. The amplification of rat GAPDH mRNA was made as a control of RNA integrity. RT was carried out for 30 min at 70°C, with Tth polymerase (2.5 U/10 l), in the presence of Mn 2+ (2.5 mmol/l). After addition of chelating buffer (EGTA 750 mol/l; Mg 2+ 2.5 mmol/l; total volume of PCR mixture was 50 l), the PCR was performed for 35 cycles at 94°C (40 s), 68°C (40 s) and 72°C profile. PCR products were analyzed on 2% agarose gel with 0.5 g/ml of ethidium bromide. The product length of the VEGF 165 was 566 bp, VEGF 121 was 434 bp and rat GAPDH was 452 bp.
Dot-blot RNA-DNA hybridization with DIG-DNA
Antisense and sense DIG-labeled DNA probes were generated by PCR using pSGV5-VEGF 165 plasmid as a template, VEGF-specific primers, 150 M DIG-dUTP, 50 M dUTP and 200 M of dATP, dCTP and dGTP. The efficiency of labeling was checked by immunohistochemical staining of membrane-bound DNA, using anti-DIG antibodies coupled with alkaline phosphatase, detected by reaction with NBT/BCIP alkaline phosphatase substrates. mRNA was isolated from total RNA using an mRNA Isolation Kit and bound with UV light to the nylon membrane. Plasmid pSG5-VEGF 165 DNA served as a positive control. Prehybridization was performed for 2 h at 42°C in a hybridization buffer (7% SDS, 50% formamide, 5 × SSC, 0.1 M phosphate buffer pH 7.0, 0.1% sarcosyl, 25 g/ml tRNA and 1% blocking reagent (Boehringer Mannheim, Mannheim, Germany). Afterwards, DIG-labeled antisense or sense DNA was added to the hybridization buffer and overnight hybridization was performed at 42°C. After intensive washing (twice at room temperature in 2 × SSC, 0.1% SDS buffer; twice at 42°C in 0.1 × SSC, 0.1% SDS) the membrane was incubated in 2% blocking reagent for 45 min followed by incubation (45 min, room temperature) with anti-DIG antibody diluted 1:2500 in blocking reagent. After intensive washing in maleic buffer (100 mM maleic Vascular Medicine 2000; 5: [33] [34] [35] [36] [37] [38] [39] [40] acid, 150 mM NaCl, pH 7.5), reaction with NBT/BCIP substrate (diluted in Tris-HCl 100 mmol/L, NaCl 100 mmol/L, MgCl 2 50 mmol/l, pH 9.5) was performed overnight in darkness at room temperature.
Immunohistochemical staining for VEGF COS7 cells were washed twice in PBS for 5 min and fixed for 1 min in acetone/methanol containing 0.3% H 2 O 2 . The mouse anti-human VEGF antibodies, diluted 1:100 in PBS/1% BSA were applied onto cells for 1 h at room temperature. The cells were washed several times with PBS and covered for 1.5 h with goat anti-mouse IgG antibody labeled with peroxidase, diluted 1:100 in PBS with 1% BSA. Afterwards the cells were washed again several times with PBS and an AEC chromogen with hydrogen peroxide (0.01%) was applied for 10 min. The reaction was monitored under a microscope. The cells were washed in water and briefly counterstained in hematoxylin.
VEGF production in VSMC transfected with pSG5-VEGF was estimated immunohistochemically using a polyclonal antibody against VEGF labeled with biotin, followed by streptavidine-alkaline phosphatase incubation and reaction with a substrate for alkaline phosphatase.
Measurements of VEGF synthesis using the ELISA Kit
VEGF was measured in medium according to the manufacturer's protocol. Each measurement was performed in duplicate.
Influence of VEGF on endothelial cell proliferation
VEGF or conditioned medium (300 l) from VSMC (cells transfected with pSG5-VEGF, pSV␤-gal plasmids, cells treated only with liposomes, or control VSMC) were added to human umbilical vein endothelial cells or to human arterial endothelial cell culture (70% confluency, starved overnight in a serum-free medium). In some experiments, medium from pSG5-VEGF transfected VSMC was preincubated for 1 h at room temperature with anti-VEGF antibodies (100 ng/ml) to block VEGF protein, and was then poured on the endothelial cells. After 24 h, 5 Ci of 3 Hthimidine was added to each well. After the next 24 h the medium was removed, the cells were lysed with scintilation fluid and cpm was measured with a LKB scintillation counter.
Statistical methods
Data are presented as means ± SD. Statistical evaluation was done with ANOVA followed by Tukey test; p Ͻ 0.05 was accepted as statistically significant.
Results
Transfection efficiency
The transfection efficiency with Lipofectamine into COS-7 cells was high. About 50% of COS-7 cells expressed ␤gal activity 24 h after transfection (Figure 1a) . In contrast, Lipofectin or Transfectam liposomes were ineffective in rat VSMC. 34 A higher transfection efficiency (about 5% of VSMC) was achieved using Maxifectin or Tfx-50 reagents (Figure 1b) . 
Expression of VEGF mRNA in transfected cells
RT-PCR demonstrated the strong expression of VEGF mRNA in transfected VSMC. A low level of endogenous VEGF mRNA was observed also in control cells (Figure 2 ). After transfection of pSG5-VEGF 121 or pSG5-VEGF 165 a strong band of the cDNA product was observed. Thus, the predominant VEGF synthesis seems to derive from the exogenous transgene, not from the endogenous VEGF expression.
To confirm that the positive signal in RT-PCR resulted from mRNA amplification and not from plasmid contamination, VEGF mRNA was isolated from the cells. Dot-blot hybridization with the antisense DIG-labeled VEGF probe clearly demonstrated that human VEGF mRNA was expressed in transfected cells (Figure 3a) . The sense probe, which detected VEGF DNA, did not hybridize with the mRNA sample (Figure 3b ).
VEGF synthesis
Although only a modest number of VSMC appeared to have been transfected, as shown by ␤-galactosidase activity of transfected cells (Figure 1b ) and by immunohistochemical staining for VEGF (not shown), the conditioned medium from these cultured VSMCs contained rather high amounts of human VEGF in the nanogram range (Table 1 ). In the medium from control cells, no or only trace amounts of immunoreactivity for VEGF were detected ( Table 1) .
The highest generation of VEGF protein after pSG5-VEGF transfection was observed 24-72 h after transfection Vascular Medicine 2000; 5: [33] [34] [35] [36] [37] [38] [39] [40] (Table 1, Figure 4 ). Later on, the synthesis of VEGF diminished ( Figure 4) .
Stimulation of endothelial cell proliferation by conditioned media from pSG5-VEGF transfected VSMC
Conditioned medium from VSMC transfected with the VEGF gene stimulated HUVEC and CAEC proliferation to a significantly greater degree than conditioned medium from ␤-gal transfected VSMC ( Figure 5 ). The potency was comparable to 10 ng of exogenous recombinant human VEGF 165 . Both pSG5-VEGF 121 ( Figure 5 ) and pSG5-VEGF 165 ( Figure 6 ) were biologically active as demonstrated by enhanced thymidine incorporation in endothelial cells treated with conditioned media. The capacity for inducing endothelial cell proliferation was completely abrogated by pre-incubation of medium with anti-VEGF antibodies ( Figure 6 ), evidence that the stimulatory effect of conditioned medium was likely due to VEGF.
Discussion
The salient finding of the present study is that, despite low transfection efficiency (typical for these cells), transfected VSMC produce sufficient amounts of VEGF protein to have a biological effect. We found that VEGF protein, released from transfected cells, accumulated in the culture media. Despite the low lipotransfection efficiency of these Mean ± SD, n = 3-6. *p Ͻ 0.001 vs pSV ␤-gal transfected liposome or control cells. cells, rarely exceeding 5%, nanogram quantities of VEGF were generated. This recombinant VEGF possessed typical mitogenic activity because the conditioned medium from pSG5-VEGF transfected cells induced the proliferation of human endothelial cells. This effect was blocked by anti-VEGF antibody, confirming that the effect of the conditioned medium was due to VEGF. The proliferation of endothelial cells was also modestly increased by conditioned media from liposome-treated or pSV␤-gal transfected cells. This effect may be due to stimulation by mitogenic factors in the serum of the media used for VSMC culture and/or by the endogenous rat VEGF released by those cells. In our complementary studies, 37 we have demonstrated that rat control or pSV␤-gal transfected VSMC can generate up to 200 pg/ml of VEGF, but this endogenous rat VEGF was not detected by the antibodies of the ELISA Kit used for measurement of human VEGF.
Vascular smooth muscle cells are resistant to lipo- transfection. It was very recently reported that some new liposome systems achieve up to 30% efficacy in rat VSMC when transfection is performed in serum-free medium. 38 However, the effectiveness of liposomal gene delivery performed in the presence of serum is very low, ranging from 0.1% to 1.2% for rabbit VSMC and about 0.1% for human or rat cells. 33 Our results for in vitro lipotransfection of rat VSMC using Lipofectin, Transfectam or Unifectin were very similar 34 to those described earlier, 33 with approximately 0.1% transfection efficiency. In contrast, new kinds of liposomal vehicles, Maxifectin and Tfx-50, permitted us to achieve 1-8% transfection efficiency (ref. 34 , this study). Even transient transgene expression in a small number of cells may have a meaningful biological effect if the gene product is secreted to have a paracrine effect on neighboring cells. 39, 40 For example, NOS gene transfer into less than 1% of vascular cells was enough to inhibit neointimal formation in isolated porcine vessels 20, 39 or to normalize blood pressure in hypertensive rats. 40 Transient expression of VEGF efficiently accelerated the re-endothelialization of vessels injured by balloon catheter and attenuated myointimal hyperplasia 15 or induced revascularization of ischemic tissue. 13, 41 Therefore, it seems that low transfection efficacy and the transient gene expression may not preclude a therapeutic effect.
In our studies we cloned both VEGF 121 and VEGF 165 into the pSG5 expression vector. Both vectors were expressed in transfected VSMC. The highest protein generation was observed between 24 and 72 h after transfection, reaching the level of 3 ng/ml (at the upper limits of detection by the ELISA Kit). Later on, the amount of synthezised VEGF decreased. This time-dependent loss of VEGF expression may be due to the loss of plasmids from transfected cells and/or inactivation of the SV40 promoter by cellular methylases. 42 Transient expression may even be desirable in order avoid side-effects associated with prolonged growth factor treatment. It may be beneficial in gene therapy of restenosis, when the long-lasting expression of therapeutic gene(s) is not necessary.
To conclude, low transfection efficiency does not pre-Vascular Medicine 2000; 5: [33] [34] [35] [36] [37] [38] [39] [40] clude the generation of biologically significant amounts of VEGF by VSMC. Thus, we suggest that the pSG5-VEGF 121 and pSG5-VEGF 165 plasmids can be used for therapeutic application.
